US equities
|
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
NVDA
$186.64
▲+2.78%
MU
$690.00
▲+5.12%
AMD
$449.04
▲+11.04%
SPCX
$134.27
▲+8.62%
AAPL
$342.37
▼-0.52%
SNDK
$835.06
▲+3.55%
MSFT
$530.61
▼-0.99%
TSLA
$358.22
▲+4.23%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Nascent Biotech Inc
(OP:
NBIO
)
0.0002
UNCHANGED
Last Price
Updated: 10:32 AM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nascent Biotech Inc
< Previous
1
2
Next >
Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
June 08, 2021
SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of...
From
Nascent Biotech Inc.
Via
AccessWire
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab
May 19, 2021
TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the...
From
Nascent Biotech Inc.
Via
AccessWire
Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
May 04, 2021
SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of...
From
Nascent Biotech Inc.
Via
AccessWire
Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt
April 26, 2021
SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of...
From
Nascent Biotech Inc.
Via
AccessWire
< Previous
1
2
Next >
